From the Center for Observational and Real-World Evidence (CORE), Merck & Co, Inc, Kenilworth, New Jersey.
Center for Observational and Real-World Evidence (CORE), Merck & Co, Inc, Boston, Massachusetts.
Anesth Analg. 2021 Dec 1;133(6):1437-1450. doi: 10.1213/ANE.0000000000005657.
Neuromuscular blockade (NMB) is a critical part of many surgical procedures. Data on practice patterns of NMB agents (NMBAs) and NMB reversal in recent years in the US ambulatory surgical care setting are limited.
This retrospective analysis of US adult outpatients was conducted using the Premier Healthcare Database. We describe anesthesia practice trends in NMB management and assess the association of patient, procedural, and site characteristics with NMB reversal approach using multivariable logistic regression.
Approximately 5.2 million outpatient surgical encounters involving NMB and 4.6 million involving rocuronium or vecuronium between January 2014 and June 2019 were included. Following the introduction of sugammadex to US clinical practice (~2016), there was an increased use of rocuronium or vecuronium and a decrease in succinylcholine alone. Before 2016, NMB was pharmacologically reversed with neostigmine in approximately two-thirds of outpatient encounters. Over time, active reversal increased; by 2019, 42.3% and 36.0% of encounters were reversed by neostigmine and sugammadex, respectively, with 21.7% undergoing spontaneous recovery. Choice of NMBA (rocuronium or vecuronium alone), time since 2016, obesity, peripheral vascular disease, and procedures on the digestive, ocular, and female genital systems (vs musculoskeletal procedures) were independently and positively associated with pharmacologic reversal (versus spontaneous reversal). Conversely, advanced age; Western geography; and cardiovascular, endocrine, hemic/lymphatic, respiratory, and ear, nose, and throat procedures were independently and negatively associated with pharmacologic reversal of NMB.Among pharmacologic reversals, time since 2016 was positively and independently associated with sugammadex compared with neostigmine (odds ratios [ORs], ranged from 1.8 in 2017 to 3.2, P < .0001 in 2019). Those administered rocuronium or vecuronium without succinylcholine, with increased age and history of certain comorbidities, and those undergoing ocular or respiratory procedures (compared with musculoskeletal) were positively associated with reversal with sugammadex and endocrine procedure negatively and independently associated with reversal with sugammadex. There was variability in the association of several factors with NMB reversal choices by geographic region, particularly in patients' race, ethnicity, and size of affiliated hospital.
Overall, active pharmacological reversal of NMB increased in US adult outpatients following the introduction of sugammadex, although there remains significant practice variability. The multifactorial relationship between patient-, procedural-, and environmental-level characteristics and NMB management is rapidly evolving. Additional research on how these anesthesia practice patterns may be impacted by the shift to the ambulatory care setting and how they may impact patient outcomes and health disparities is warranted.
神经肌肉阻滞(NMB)是许多外科手术的关键部分。近年来,美国门诊手术护理环境中 NMB 药物(NMBAs)和 NMB 逆转的实践模式数据有限。
本研究使用 Premier Healthcare Database 对美国成年门诊患者进行了回顾性分析。我们描述了 NMB 管理中的麻醉实践趋势,并使用多变量逻辑回归评估了患者、手术和手术部位特征与 NMB 逆转方法的关联。
2014 年 1 月至 2019 年 6 月期间,共纳入了约 520 万例涉及 NMB 的门诊手术和 460 万例涉及罗库溴铵或维库溴铵的手术。在 sugammadex 引入美国临床实践后(约 2016 年),单独使用罗库溴铵或维库溴铵的使用增加,而单独使用琥珀胆碱的使用减少。在 2016 年之前,大约三分之二的门诊手术使用新斯的明进行药理学逆转。随着时间的推移,主动逆转增加;到 2019 年,42.3%和 36.0%的手术分别通过新斯的明和 sugammadex 逆转,21.7%的手术自发恢复。NMBA 的选择(单独使用罗库溴铵或维库溴铵)、自 2016 年以来的时间、肥胖、周围血管疾病以及消化系统、眼部和女性生殖系统(与肌肉骨骼手术相比)的手术与药理学逆转(与自发恢复相比)独立且呈正相关。相反,年龄较大;西部地理位置;心血管、内分泌、血液/淋巴、呼吸和耳、鼻、喉手术与药理学逆转独立且呈负相关。在药理学逆转中,自 2016 年以来的时间与 sugammadex 相比与新斯的明呈正相关且独立相关(比值比[ORs],2017 年为 1.8,2019 年为 3.2,均<0.0001)。那些接受罗库溴铵或维库溴铵而不接受琥珀胆碱的患者,年龄较大且有某些合并症病史,以及接受眼部或呼吸手术(与肌肉骨骼手术相比)的患者,与 sugammadex 逆转呈正相关,而内分泌手术与 sugammadex 逆转呈负相关且独立相关。地理位置不同,一些因素与 NMB 逆转选择的关联存在差异,尤其是患者的种族、民族和附属医院的规模。
总体而言,在 sugammadex 推出后,美国成年门诊患者中 NMB 的主动药理学逆转有所增加,但仍存在显著的实践差异。患者、手术和环境水平特征与 NMB 管理之间的多因素关系正在迅速演变。需要进一步研究这些麻醉实践模式如何受到向门诊护理环境转移的影响,以及它们如何影响患者的结果和健康差异。